Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

Shares of AKTX opened at $3.90 on Friday. The firm has a 50 day moving average of $2.67 and a 200 day moving average of $2.26. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its position in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. 5.06% of the stock is owned by institutional investors and hedge funds.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.